| Acceptance rate | 46% |
|---|---|
| Time to first decision | 20 days* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2018 , Vol 56 , Num 1
Estimation of Abiraterone in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry
1 Norwich Clinical Services Pvt. Ltd., BA & MW, Bangalore, Karnataka, IndiaDOI : 10.23893/1307-2080.APS.05605 A LCMS/MS method for the determination of abiraterone in human plasma was described. After extraction of sample from plasma by LLE method it was dried and reconstituted in mobile phase. 20?L of sample was injected to a C18 column and eluted with a mobile phase (2 mM Ammonium formate, pH 3.5: Acetonitrile: 30:70, v/v) at a flow rate of 1.2 mL/min. MRM transitions were monitored as m/z 350.3 ? 156.1 (abiraterone) and m/z 354.3 ? 160.1 (abiraterone D4). Sample concentrations were calculated by linear regression analysis using the analyst software 1.5.1. An excellent linear response was obtained over the concentration ranges 0.20 ng/mL to 79.50 ng/mL. The intra-day and inter-day precision were within 14.4%. The assay accuracy was 91.35?105.05%. Mean recovery was 60.20% (2.84%) for abiraterone. The limit of detection was 0.052 ng/mL. The stability issue of abiraterone in plasma was also addressed. This method can be used for bioequivalence studies. Keywords : abiraterone, prostate cancer, LLE, LCMS/MS, validation